Preclinical characterization of a novel diphenyl benzamide selective ERα agonist for hormone therapy in prostate cancer

Christopher C CossJames T Dalton


Androgen deprivation therapy (ADT) is the mainstay of treatment for advanced prostate cancer. ADT improves overall and disease-free survival rates, but long-term therapy is associated with severe side effects of androgen and estrogen depletion including hot flashes, weight gain, depression, and osteoporosis. Effective hormone reduction can be achieved without estrogen deficiency-related side effects by using therapy with estrogenic compounds. However, cardiovascular complications induced by estrogens coupled with the availability of LHRH agonists led to discontinuation of estrogen use for primary androgen deprivation therapy in the 1980s. New treatments for prostate cancer that improve patient outcomes without the serious estrogen deficiency-related toxicities associated with ADT using LHRH analogs are needed. Herein we describe a novel nonsteroidal selective estrogen receptor-α agonist designed for first-line therapy of advanced prostate cancer that in animal models induces medical castration and minimizes many of the estrogen deficiency-related side effects of ADT. The present studies show that orally administered GTx-758 reversibly suppressed testosterone to castrate levels and subsequently reduced prostate volume and circul...Continue Reading


Apr 1, 1976·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·L K Cheng, H L Fung
Jan 1, 1975·Vitamins and Hormones·G JönssonE Diczfalusy
Mar 1, 1976·Journal of Toxicology and Environmental Health·L J FischerK L Hintze
Apr 1, 1991·Journal of Bone and Mineral Research : the Official Journal of the American Society for Bone and Mineral Research·J G SeedorD D Thompson
Oct 1, 1990·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C K OsborneR A Chapman
Aug 17, 1989·The New England Journal of Medicine·E D CrawfordP J Goodman
Apr 1, 1987·Canadian Journal of Physiology and Pharmacology·M J Katovich, J O'Meara
Nov 15, 1984·The New England Journal of Medicine·UNKNOWN Leuprolide Study Group
Mar 1, 1982·Proceedings of the National Academy of Sciences of the United States of America·G TolisA V Schally
May 1, 1980·The Journal of Urology·R M DobbsJ E Bergin
Dec 1, 1995·The Journal of Urology·R L Cox, E D Crawford
Jan 1, 1996·The Prostate·W E Farnsworth
Jun 1, 1996·AJR. American Journal of Roentgenology·A SerraS Ruyle
Jul 3, 1996·Journal of the National Cancer Institute·C N RobertsonR L Fine
Dec 22, 1999·The Journal of Urology·H W DaniellP T Stratte
Jul 27, 2001·Brazilian Journal of Medical and Biological Research = Revista Brasileira De Pesquisas Médicas E Biológicas·L H da PazV Jorgetti
Sep 29, 2001·The New England Journal of Medicine·M R SmithJ S Finkelstein
Apr 17, 2002·The Journal of Urology·Robert W Ross, Eric J Small
Jun 5, 2002·Nature Reviews. Cancer·Samuel R Denmeade, John T Isaacs
Feb 14, 2003·The New England Journal of Medicine·B Lawrence Riggs, Lynn C Hartmann
Apr 28, 2004·Breast Cancer Research and Treatment·Michael D JohnsonTodd C Skaar
Jan 14, 2005·The New England Journal of Medicine·Vahakn B ShahinianJames S Goodwin
Aug 5, 2005·The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences·Muthuvel JayachandranVirginia M Miller
Nov 1, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R SmithChris L Pashos
Feb 3, 2006·Journal of Medicinal Chemistry·Owen B WallaceThomas P Burris
Feb 8, 2006·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Jeannine S McCuneJanet L Espirito
Jan 24, 2007·Clinical Genitourinary Cancer·Jennifer L LycetteTomasz M Beer
Mar 21, 2007·International Journal of Cancer. Journal International Du Cancer·Adam GondosHermann Brenner
Feb 13, 2008·British Journal of Cancer·G NormanA J Eastwood
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Matthew R SmithMitchell S Steiner
Sep 2, 2008·Seminars in Cell & Developmental Biology·Ian R Reid

❮ Previous
Next ❯


May 30, 2013·Expert Opinion on Therapeutic Patents·Ilaria PaterniFilippo Minutolo

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.